Cara Therapeutics Inc CARA:NASDAQ

RT Quote | NASDAQ | USD
Last | 02/02/23 EST
11.95quote price arrow up+0.09 (+0.76%)
Volume
252,958
52 week range
7.40 - 13.96
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close11.95
  • 52 Week High13.96
  • 52 Week High Date04/18/22
  • 52 Week Low7.40
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap642.07M
  • Shares Out53.73M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.96
  • YTD % Change11.27

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close11.95
  • 52 Week High13.96
  • 52 Week High Date04/18/22
  • 52 Week Low7.40
  • 52 Week Low Date05/09/22
  • Market Cap642.07M
  • Shares Out53.73M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.96
  • YTD % Change11.27

RATIOS/PROFITABILITY

  • EPS (TTM)-1.66
  • P/E (TTM)-7.19
  • Fwd P/E (NTM)-16.67
  • EBITDA (TTM)-89.50M
  • ROE (TTM)-45.16%
  • Revenue (TTM)39.43M
  • Gross Margin (TTM)84.89%
  • Net Margin (TTM)-224.51%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date02/27/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cara Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical...
Christopher Posner
President, Chief Executive Officer, Director
Ryan Maynard
Chief Financial Officer
Address
4 Stamford Plaza
107 Elm Street 9Th Floor
Stamford, CT
06902
United States

Top Peers

SYMBOLLASTCHG%CHG
SRRK
Scholar Rock Holding Corp
12.37+0.14+1.14%
PTGX
Protagonist Therapeutics Inc
14.46+0.40+2.84%
NRIX
Nurix Therapeutics Inc
13.26+0.90+7.28%
MRUS
Merus NV
16.07+0.71+4.62%
EDIT
Editas Medicine Inc
11.53+1.12+10.76%